Document:

gthp_ex1059

 

Exhibit 10.59

 

Guided
Therapeutics, Inc.

5835
Peachtree Comers East, Suite B

Norcross,
GA 30092

 

Re:
Finder's Fee Agreement

Dear
Gene Cartwright:

 

As
you know, Guided Therapeutics, Inc. (the ' Issuer"), has expressed
an interest in obtaining private equity or debt capital for various
purposes. This letter agreement ("Agreement") sets forth the terms
and conditions upon which

 

J.H.
Darbi.e & Co., Inc. ("Darbie"), will introduce the Issuer to
third-party investors (each, an "Introduced
Party”).

 

1.
Nature of Agreement and Services.

 

(a)
Promptly upon execution of this Agreement by the issuer, Darbie
will use its best efforts to initiate an introductory meeting
between principals of the Introduced Party and the Issuer to
discuss a possible Transaction (as defined herein). The Issuer
understands that Darbie is not guaranteeing that a Transaction will
be consummated, is not offering to purchase any securities of the
Issuer and is not obligated to provide any additional services
beyond the scope of this Agreement.

 

(b)
Issuer is not at the time of this Agreement a customer, affiliate,
or representative of Darbie.

 

(c)
Darbie is not providing any recommendation to the Issuer in
connection with any possible Transaction.

 

(d)
Darbie has not provided any investment banking, advisory, or
analytic services to the Issuer, including underwriting or
placement agent services, either as principal or agent, in
connection with the offer or sale of any securities of the
Issuer.

 

(e) Darbie is not and will not be a party to any
contract entered into between the 1ssuer and any Introduced
Party(f) Darbie will not participate in any way in fulfilling any
obligations to any Introduced Party undertaken, by the Issuer,
including services relating to the offer or sale of securities,
such as: (i) performing any independent analysis of the offer or
sale of securities; ii) engaging in any due diligence activities;
(iii) assisting in or providing financing for such pm-chases; (iv)
providing any advice relating to the valuation of or the financial
advisability of such an investment; (v) advising or providing
infom1ation regarding the suitability of any investment for any
person; or (vi) handling any funds or
securities.

 

 

 

 

2.
Term.

 

(a) This Agreement will
remain in effect for a period of 30 days from its date (the
"Term"). Darbie will have the right to terminate this Agreement
upon five days' prior written notice to the Issuer. The Issuer
will not have the right to
terminate this Agreement unless there has been a breach by Darbie
of a material term of this Agreement, and the Issuer has provided
Darbie with written notice of such breach; provided, however,
Darbie will have the right to cure
such breach within 10 days of the date of the notice sent by the
Issuer. Notwithstanding termination of this Agreement, Darbie will
be entitled to receive compensation under section 3 in the event
the Issuer and an Introduced Party consummate a Transaction (as
defined herein) at any tune during the Term, commencing on the date
hereof Sections 2, 3,6,8, and 11 will survive termination of this
Agreement.

 

(b)
If during the Term, an Introduced Party enters into an agreement to
purchase securities from the Issuer, which is consummated at: any
time thereafter; each of the foregoing, a "Transaction." the Issuer
will pay Darbie, upon the receipt of the purchase price for the
securities or the close of the Transaction, a Finder's Fee in the
amount that would otherwise have been payable to Darbie in
accordance with this Agreement had such Transaction occurred during
the Term.

 

3. Finder's Fee and
Expenses.

 

(a) In consideration of the foregoing, upon
consummation of the closing regarding a financing on behalf of the
Issuer, directly or through a structured Transaction,
Darbie
will be entitled to receive a finder fee ("Finder's Fee") in cash
equal to 2% of the gross proceeds of an equity convertible debt
transaction and 2% of the gross proceeds of a debt transaction
received by the Issuer within three business days from the closing
date. The Issuer and the
Introduced Party will not be obligated to pay Darbie if the Issuer
does not receive the Transaction Proceeds for any reason
whatsoever.

 

(b) In the event that the Issuer proceeds with a
non-financing transaction with one or more Introduced Parties, then
prior to closing the Issuer and Darbie shall mutually agree upon
compensation payable to Darbie which may include an ownership
interest in the resulting licensed, joint venture and/or
merged/acquiring entity. III the event the Issuer completes a
non-financing transaction with an Introduced Party without first
agreeing with Darbie on the finder's fee for the non-financing
transaction. then Darbie shall be entitled to receive a cash fee
equal to 3% of any licensing fees payable upon receipt by the
licensor, a cash fee equal to 3% of the value of the Issuer related
portion of the surviving entity resulting from any merger or
acquisition payable upon closing of the transaction and, in the
case of a joint venture, equal to 3% of Darbie's ownership portion
of the joint venture.

 

(c) The Finder's Fee will
be paid in cash and will be payable whether or not the Transaction
involves equity or debt securities, or a combination of equity and
debt securities and cash or is made on the installment-sale basis. The Finder's Fee
will be deducted from the Transaction Proceeds by the Introduced
Party, and the introduced Party will remit the Finder's Fee
directly to Darbie on Issuer's behalf. For purposes of this
Agreement "Transaction Proceeds" will mean the fair market value of
all cash and securities received by the Issuer from the Introduced
Party, including a debt repayment or debt assumption, all
determined in accordance with generally accepted accounting
principles. Notwithstanding the foregoing, in the event that the
Transaction Proceeds are received by the Issuer in installments,
the compensation payable to Darbie hereunder will be due and
payable upon receipt by the Issuer of each installment in the same
manner described earlier in this section.

 

(d)
Darbie will be solely liable for the payment of any taxes imposed
or arising out of any Finder's Fee received by it under this
Agreement.

 

(e) Issuer agrees to not circumvent Darbie by
entering into business relations with any Introduced Party without
providing payment of the agreed upon Finder's Fee as stated
in this Agreement.

 

(f)
Issuer and Darbie will each pay its own expenses arising out of or
relating to this Agreement.

 

(g)
Preexisting Relationship. In the event Issuer has prior evidentiary
communication with an Introduced Parry, the Issuer will notify
Darbie of such a relationship and, upon written request, provide
documentation of the Issuer's prior communication with an
Introduced Party. Communication will include phone or e-mail
contact or written representations
by both Issuer and an Introduced Party of a preexisting
relationship. For purposes of this paragraph, email communication
is deemed acceptable.

 

 

 

 

Guided
Therapeutics, Inc.

5/14/2020

Page
3

 

(h)
Darbie's Representations and Warranties. Darbie, a registered
broker-dealer, represents and warrants that: (a) it is not
prohibited by any legal contractual, fiduciary, or other obligation
from receiving a Finder's Fee; (ii) it has the full legal authority
and capacity to sign this Agreement; (iii) it is acting merely as a
tinder and will not provide investment banking or related services
to Issuer or any potential Introduced Parties; and (iv) no other
person or entity is entitled to or has arty claim to the Finder's
Fee or arty portion thereof. Darbie agrees to notify the Issuer
promptly if any of the foregoing representations ceases to be
true.

 

(i)
Confidential Information. Darbie will hold in confidence, for a
period of two years from the date hereof, any confidential
information that the Issuer may provide to it pursuant to this
Agreement unless the Issuer gives Darbie permission in writing to
disclose such confidential information to a specific third party.
Notwithstanding the foregoing, Darbie will not be required to
maintain confidentiality for information: (a) that is or becomes
part of the public domain through no fault or action of Darbie; (b)
of which it had independent knowledge prior to disclosure to it by
the Issuer; (c) that comes into Darbie's possession in the normal
and routine course of its own business from and through
independent, nonconfidential sources; or (d) that is required to be
disclosed by Darbie by governmental or security regulatory
requirements. If Darbie is requested or required (by oral
questions, interrogatories, requests for information or document
subpoenas, civil investigative demands, or similar process) to
disclose any confidential information supplied to it by the Issuer
or the existence of other negotiations in the course of its
dealings with the Issuer or its representatives, Darbie will,
unless prohibited by law, promptly notify the Issuer of such a
request so that the Issuer may seek an appropriate protective
order.

 

(j)
Independent Contractor. Nothing in this Agreement win constitute a
business combination, joint venture, partnership or employment
relationship between the Issuer and Darbie. Darbie acknowledges and
agrees that it is merely and strictly acting as a finder, and not
as an agent, employee, or representative of the Issuer, and has no
authority to negotiate for or to bind the issuer. This Agreement is
not exclusive, and each party is free to enter into similar
arrangements with third parties. Darbie agrees it will not make,
publish, or distribute any advertisement or marketing material
using the trademarks, logos, trade names or abbreviations thereof,
or any other such identifying mark or name of the Issuer or its
affiliates without the prior consent of the Issuer.

 

(k) Indemnification. Each party hereto agrees to
indemnify and hold harmless the other parry and its officers,
directors, employees, agents, representatives, and controlling
persons (and the officer's, directors, employees, agents,
representatives, and controlling persons of each of them) (as such
are defined in Section 20 of the Securities Exchange Act of 1934,
as amended), from and against any and all losses, claims, damages:
liabilities, costs, and expenses (and all actions, suits,
proceedings, or claims in respect thereof) and any legal or other
expenses in giving testimony or furnishing documents in response to
a subpoena or otherwise (including the cost of investigating,
preparing, or defending any such action, suit, proceeding or claim,
whether or not in connection with any action, suit, proceeding, or
claim in which Darbie or the Issuer is a party), as and when incurred, directly
or indirectly, caused by, relati.ng to, based upon, or arising out
of Darbie's service pursuant to this Agreement, including any suit
based upon the terms and conditions of a Transaction or
information, representations, or warranties provided by the Issuer
to a Transaction party by the Issuer. The Issuer further agrees
that Darbie will incur no liability to the Issuer for any acts OJ
omissions by Darbie arising out of or relating to this Agreement or
Darbie's performance or failure to perform any services under this
Agreement, except for: (a) Darbie's intentional or willful
misconduct; or (b) information regarding Darbie that is provided by
Darbie to the Issuer or to a Transaction party. Further, in no
event will Darbie be liable to the Issuer or to any third party or
Transaction party for an amount in excess of the cash compensation
received pursuant to section 3 hereof. This section 8 will survive
the termination of this Agreement. Notwithstanding the foregoing,
no party otherwise entitled to indemnification will be entitled
thereto to the extent such party has been determined to have acted
in a manner that has been deemed as gross negligence or willful
misconduct regarding the matter for which indemnification is sought
herein.

 

 

 

 

Guided
Therapeutics, Inc.

5/14/2020

Page
4

  

(I)
Notices. Any notice, demand, request, or other communication
permitted or required under this Agreement will be in writing and
will be deemed to have been given as of the date so delivered, if
personally delivered; as of the date so sent, if sent by electronic
mail and receipt is acknowledged by the recipient; and one day
after the date so sent, if delivered by overnight courier service;
addressed as follows:

 

If
to the Issuer:

Guided
Therapeutics, Inc.

5835
Peachtree Comers East Suite B

Norcross,
GA 30092

 

Email:
gcartwright@guidedinc.com

If
to Darbie, to: J H Darbie & Co.,Inc.

40
Wall Street New York, NY l0005

Email:
ib@jhdarbie.com

 

Notwithstanding
the foregoing, service or legal process or other similar
communications will not be given by electronic mail and will not be
deemed duly given under this Agreement if delivered by such means.
Each party, by notice duly given in accordance herewith, may
specify a different address for the giving of any notice
hereunder.

 

(m)
Successors and Assigns. No party will assign its rights, duties,
and obligations under Agreement without the written consent of the
other party, which will not be unreasonably withheld, except as
otherwise specifically contemplated in this Agreement. This
Agreement will be binding upon, inure to the benefit of, and be
enforceable by the parties and their permitted successors and
assigns.

 

(n)
Governing Law and Enforcement. This Agreement will be governed by
and constructed under and in accordance with the laws of the state
of New York, without giving effect to any choice or conflict of law
provision or rule (whether the state of New York or any other
jurisdiction) that would cause the application of the laws of any
jurisdiction other than the state of New York. All matters
involving the Issuer and Darbie, whether arising under this
Agreement or otherwise will be heard and determined by mediation or
arbitration.

 

(o)
Entire Agreement. This Agreement incorporates and includes all
prior negotiations, correspondence, conversations, agreements, or
understandings applicable to the matters contained herein, and the
parties agree that there are no commitments, agreements, or
understandings concerning the subject matter of this Agreement that
are not contained in this document. The parties acknowledge that,
in deciding to enter into this Agreement, they have not relied upon
any statements, promises, or representation!>, written or oral,
express or implied, other than those set forth in tills Agreement.
Accordingly, it is agreed that no deviation from the terms hereof
will be predicated upon any prior representations or agreements,
whether oral or written. The parties acknowledge that they have
negotiated this Agreement at arm's-length with adequate
representation on an equal basis, and the filing of a suit
challenging the negotiated terms of this Agreement by either party
will be deemed a default and this Agreement will be terminated as
provided herein.

 

 

 

 

Guided
Therapeutics, Inc.

5/14/2020

Page
5

  

(p)
Amendment. Any amendment, modification, or waiver of the terms of
this Agreement must be executed in writing by both
parties.

 

(q)
Severability. The provisions of this Agreement are severable and
should any provision hereof be void, voidable, or unenforceable
under any applicable law, such void, voidable, or unenforceable
provision will not affect or invalidate any other provision of this
Agreement, which will continue to govern the relative rights and
duties of the parties as though the void, voidable, or
unenforceable provision was not a part hereof. In addition, it is
the intention and agreement of the parties that all the terms and
conditions hereof be enforced to the fullest extent permitted by
law.

 

(r)
Warranty of Authority. Each of the individuals signing this
Agreement on behalf of a party hereto warrants and represents that
such individual is duly authorized and empowered to enter in this
Agreement and bind such party hereto.

 

(s)
Counterpart Signatures. This Agreement may be executed in any
number of counterparts (and any counterpart may be executed by
original, portable document format (pdf), or facsimile signature)
each of which when executed and delivered will be deemed an
original, but all of which will constitute one and the same
instrument.

 

If
the foregoing is acceptable to you, please so indicate by signing
in the space provided below and returning a signed copy of this
Agreement to us for our records.

 

Sincerely,

J H
DARBlE & CO., INC.

 

 

Agreed to and accepted this
19 day
of May, 2020.

Issuer:
Guided Therapeutics,
Inc.

Name:/Gene
Cartwright/

Title:
CEOgthp_ex1060

 

Exhibit 10.60

 

EXCHANGE
AGREEMENT

 

This
EXCHANGE AGREEMENT (this “Agreement”) is made and
entered into effective as of May 22, 2020, by and between GUIDED
THERAPEUTICS, INC., a Delaware corporation (the “Company”) and Auctus
Fund, LLC, a Delaware limited liability company (the
“Creditor”).

 

W I
T N E S S E T H :

 

WHEREAS, the
Creditor is the payee of certain obligations owed to the Creditor
by the Company as set forth in the convertible promissory notes
listed on Exhibit A
hereto (the “Notes”) (the collective obligations under
the Notes shall referred to herein as the “Obligations”);

 

WHEREAS, in
satisfaction in full of the Obligations, the Creditor is willing to
accept the Cash Payments (as defined in this Agreement) and
Securities (as defined in this Agreement) (the “Exchange”);

 

WHEREAS, the
Exchange is being made in reliance upon the exemption from
registration provided by Section 4(a)(2) of the Securities
Act.

 

WHEREAS, the
Company and the Creditor desire to enter into this Agreement to
evidence and set forth the terms of the exchange of the Cash
Payments and Securities (as defined in this Agreement) for and in
satisfaction of the Obligations;

 

NOW,
THEREFORE, in consideration of the mutual covenants herein
contained, and intending to be legally bound hereby, the parties
hereto, being duly sworn, do covenant, agree and certify as
follows:

 

1.           Recitals.
The parties hereto acknowledge and agree that the foregoing
recitals are true and accurate and constitute part of this
Agreement to the same extent as if contained in the body
hereof.

 

2.           Definitions.
In addition to the terms defined elsewhere in this Agreement: (a)
capitalized terms that are not otherwise defined herein have the
meanings given to such terms in the Obligations, and (b) the
following terms have the meanings set forth in this Section
1.1:

 

“Affiliate” means any
Person that, directly or indirectly through one or more
intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed
under Rule 405 under the Securities Act.

 

“Board of Directors” means
the board of directors of the Company.

 

“Common Stock” means the
common stock of the Company, par value $0.001 per share, and any
other class of securities into which such securities may hereafter
be reclassified or changed.

 

 

 

 

“Exchange Act” means the
Securities Exchange Act of 1934, as amended, and the rules and
regulations promulgated thereunder.

 

“Liens” means a lien,
charge, pledge, security interest, encumbrance, right of first
refusal, preemptive right or other restriction.

 

“Person” means an
individual or corporation, partnership, trust, incorporated or
unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or
subdivision thereof) or other entity of any kind.

 

“Securities” has the
meaning set forth in the Preamble of this Agreement.

 

“Securities Act” means the
Securities Act of 1933, as amended, and the rules and regulations
promulgated thereunder.

 

3.           Exchange
and Satisfaction. The
Obligations will be exchanged for the Cash Payments (as defined
below), Securities and other considerations according to the
following terms and conditions and pursuant to the terms of this
Agreement:

 

a.

The Creditor will
receive $160,000 in cash payments (the “Cash Payments”)
according to the following schedule:

 

●

$20,000 on or
before May 30, 2020 (the “Initial Payment”);
and

●

$20,000 every
thirty (30) calendar days thereafter for seven consecutive calendar
months (a total of $140,000.00).

 

b.

In addition to the
Cash Payments, the Creditor will be entitled to convert a portion
of the Notes pursuant to the original terms of the Notes into
500,000 shares of the Company’s common stock (the
“First Shares”). The sale of the First Shares by the
Creditor shall be restricted until November 1, 2020, according to
the following schedule:

i.

200,000 shares
cannot be sold unless the market share price is above 15
cents.

ii.

150,000 shares
cannot be sold unless the marker share price is above 20
cents.

iii.

150,000 shares
cannot be sold unless the market share price is above 25
cents.

 

c.

On the Effective
Date, the Company shall issue to Creditor a common stock purchase
warrant for the purchase of 700,000 shares of the Company’s
common stock (the “Warrant”), a form of which us
attached hereto as Exhibit
B.

 

d.

For the avoidance
of doubt, the Creditor shall be subject to the beneficial ownership
limitations with respect to the Company’s common stock
provided in the Notes at all times.

 

e.

Notwithstanding
anything in this Agreement to the contrary, if the Company fails to
timely make any of the Cash Payments to Creditor and/or the Company
fails to comply with the terms of this Agreement, then Creditor may
declare this Agreement null and void and of no further force or
effect in Creditor’s sole discretion (provided , however,
that the Creditor shall retain all rights with respect to the
Warrant even if this Agreement is declared a null and void and of
no further force or effect).

 

 

2

 

 

4.           Representations
and Warranties of the Company. The Company hereby makes the following
representations and warranties to Creditor:

 

(a) Authorization; Enforcement. The
Company has the requisite corporate power and authority to enter
into and to consummate the transactions contemplated by this
Agreement and otherwise to carry out its obligations hereunder. The
execution and delivery of this Agreement by the Company and the
consummation by it of the transactions contemplated hereby and
thereby have been duly authorized by all necessary action on the
part of the Company and no further action is required by the
Company, the Board of Directors or the Company’s stockholders
in connection herewith or therewith. This Agreement have been (or
upon delivery will have been) duly executed by the Company and,
when delivered in accordance with the terms hereof and thereof,
will constitute the valid and binding obligations of the Company
enforceable against the Company in accordance with their terms,
except: (i) as limited by general equitable principles and
applicable bankruptcy, insolvency, reorganization, moratorium and
other laws of general application affecting enforcement of
creditors’ rights generally, (ii) as limited by laws relating
to the availability of specific performance, injunctive relief or
other equitable remedies and (iii) insofar as indemnification and
contribution provisions may be limited by applicable
law.

 

(b) Issuance of the Securities. The
Securities are duly authorized and, when issued and paid for in
accordance with this Agreement, will be duly and validly issued,
fully paid and nonassessable, free and clear of all Liens imposed
by the Company. The shares of Common Stock underlying the
Securities (if any), when issued in accordance with the terms of
the Securities, will be validly issued, fully paid and
nonassessable, free and clear of all Liens imposed by the Company
other than restrictions on transfer required by law. The
Creditor’s holding period with respect to such Securities and
the Common Stock underlying the Securities shall tack back to the
original acquisition date of the Obligations pursuant to Section
3(a)(9) of the Securities Act.

 

5.           Representations
and Warranties of the Creditor. Creditor hereby represents
and warrants as of the date hereof and as of the Closing Date to
the Company as follows (unless as of a specific date
therein):

(a)          Own
Account. Creditor understands that the Securities are
“restricted securities” and have not been registered
under the Securities Act or any applicable state securities law and
is acquiring the Securities as principal for its own account and
not with a view to or for distributing or reselling such Securities
or any part thereof in violation of the Securities Act or any
applicable state securities law, has no present intention of
distributing any of such Securities in violation of the Securities
Act or any applicable state securities law and has no direct or
indirect arrangement or understandings with any other persons to
distribute or regarding the distribution of such Securities in
violation of the Securities Act or any applicable state securities
law (this representation and warranty not limiting such
Creditor’s right to sell the Securities pursuant to a
registration statement or otherwise in compliance with applicable
federal and state securities laws). The Creditor is acquiring the
Securities hereunder in the ordinary course of its
business.

 

3

 

 

(c)          Creditor’s
Status. At the time the Creditor was offered the Securities,
it was, and as of the date hereof it is, an “accredited
investor” as defined in Rule 501(a) under the Securities
Act.

 

(d)          Experience
of Creditor. Creditor, either alone or together with its
representatives, has such knowledge, sophistication and experience
in business and financial matters so as to be capable of evaluating
the merits and risks of the prospective investment in the
Securities, and has so evaluated the merits and risks of such
investment. Such Creditor is able to bear the economic risk of an
investment in the Securities and, at the present time, is able to
afford a complete loss of such investment.

 

6.           Release.
The Creditor acknowledges and agrees that it shall have no further
rights or interest in, and shall not receive any further
consideration, payment or distribution of any kind with respect to,
the Obligations, except as provided in this Agreement. In such
regard, the Creditor hereby waives, relinquishes, remises and
releases all rights, claims, interests or liabilities, known and
unknown, of any nature whatsoever in law or equity which the
Creditor may previously have had or may now or hereafter have as
against or to receive from the Company arising out of, resulting
from or relating to the Obligations or any rights or interest of
the Creditor with respect thereto, except as provided in this
Agreement. The Company acknowledges and agrees that it shall have
no further rights or interest in, and shall not receive any further
consideration, payment or distribution of any kind with respect to,
the Obligations, except as provided in this Agreement. In such
regard, the Company hereby waives, relinquishes, remises and
releases all rights, claims, interests or liabilities, known and
unknown, of any nature whatsoever in law or equity which the
Company may previously have had or may now or hereafter have as
against or to receive from the Creditor arising out of, resulting
from or relating to the Obligations or any rights or interest of
the Company with respect thereto, except as provided in this
Agreement

 

7.           Transfer
Restrictions. The Securities may only be disposed of in
compliance with state and federal securities laws. In connection
with any transfer of Securities other than pursuant to an effective
registration statement or Rule 144 under the Securities Act or
other applicable exemption, the Company may require the transferor
thereof to provide to the Company an opinion of counsel selected by
the Creditor, the form and substance of which opinion shall be
reasonably satisfactory to the Company, to the effect that such
transfer does not require registration of such transferred
Securities under the Securities Act.

 

8.           Further
Assurances. The
Creditor shall hereafter, without further consideration, execute
and deliver promptly to the Company such further consents, waivers,
assignments, endorsements and other documents and instruments, and
to take all such further actions, as the Company may from time to
time reasonably request with respect to the Exchange and
satisfaction of the Obligations and the consummation in full
thereof. The Company shall hereafter, without further
consideration, execute and deliver promptly to the Creditor such
further consents, waivers, assignments, endorsements and other
documents and instruments, and to take all such further actions, as
the Creditor may from time to time reasonably request with respect
to the Exchange and satisfaction of the Obligations and the
consummation in full thereof.

 

 

4

 

 

9.           Successors
and Assigns. This
Agreement is binding upon, and shall inure to the benefit of, the
parties hereto and their respective successors and assigns,
provided, however, that any assignment of the rights and benefits
hereunder by the Company must be agreed to in a signed writing by
the Creditor.

 

10.           Counterparts.
This Agreement may be executed in multiple counterparts, each of
which shall be deemed an original and all of which, when taken
together, shall constitute one and the same
instrument.

 

 

IN
WITNESS WHEREOF, the parties hereto have affixed their hands and
seals by signing this Agreement as of the day and year first above
written.

 

Company:

 

GUIDED
THERAPEUTICS, INC.

 

 

By:
/Gene S. Cartwirght

Name:
Gene S. Cartwright

Title:
President and CEO

 

 

 

Creditor:

 

Auctus
Fund, LLC

 

 

By:
/Lou Posner

Name:
Lou Posner

Title:
Managing Director

 

 

5

 

Exhibit
A

 

1.

That certain
convertible promissory note in the original principal amount of
$150,000.00 dated March 20, 2018

 

2.

That certain
convertible promissory note in the original principal amount of
$89,250.00 dated July 3, 2018.

 

3.

That certain
convertible promissory note in the original principal amount of
$65,000.00 dated March 29, 2019.

 

 

 

6

 

Exhibit
B

 

(see
attached)

 

7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}]]